Corona Remedies Ltd: Q1FY27 results
Corona Remedies Ltd reported revenue of Rs 422 cr and net profit of Rs 60 cr for Q1FY27.
Filed 31 Jul 2026, 17:32 IST · after market close · Corona Remedies Ltd (CORONA)
Price around the results
What was reported
Corona Remedies Ltd reported revenue of Rs 422 cr and net profit of Rs 60 cr for Q1FY27. Figures are consolidated.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹422 cr |
| Other income | ₹3 cr |
| Expenses | ₹329 cr |
| Operating profit | ₹93 cr |
| Operating margin (%) | 22.05% |
| Interest | ₹3 cr |
| Depreciation | ₹13 cr |
| Profit before tax | ₹80 cr |
| Tax | ₹20 cr |
| Net profit | ₹60 cr |
| EPS (₹) | ₹9.83 |
Operating margin of 22.05% compares with a Healthcare sector median of 26.13% across 24 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company reports that an additional 400 million tablets of commercial production commenced at the Gujarat facility on 22 December 2025.
Guidance & outlook
- The Indian pharmaceutical market is expected to grow at a CAGR of 8–9% until FY30.
- Growth in the chronic segment is expected to outpace the acute segment.
Expansion
- An additional 400 million tablets of commercial production commenced at the Gujarat facility on 22 December 2025.
New products
- The company plans to launch products addressing unmet patient needs within existing therapeutic areas.
New initiatives
- The company plans to intensify engagement with super-specialist prescribers in metro, semi-metro and urban centres through its MR network.
- The company plans to expand into nephrology, CNS, rheumatology, dermatology and gastroenterology.
- The company plans strategic acquisitions and in-licensing to enter complementary and newer therapy areas.
- The company is investing in employee training, which increased by 50%.
Competition
- The company reports 18.4% revenue MAT growth, the fastest growth among the top 30 Indian pharmaceutical peers.
- The company says its market share gains are supported by volume growth, new launches, geographical expansion and field-force expansion.